Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.

Cerhan JR, Natkunam Y, Morton LM, Maurer MJ, Asmann Y, Habermann TM, Vasef MA, Cozen W, Lynch CF, Allmer C, Slager SL, Lossos IS, Chanock SJ, Rothman N, Hartge P, Dogan A, Wang SS.

Leuk Lymphoma. 2012 Jun;53(6):1105-12. doi: 10.3109/10428194.2011.638717. Epub 2012 Jan 3.

2.

LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.

Colomo L, Vazquez I, Papaleo N, Espinet B, Ferrer A, Franco C, Comerma L, Hernandez S, Calvo X, Salar A, Climent F, Mate JL, Forcada P, Mozos A, Nonell L, Martinez A, Carrio A, Costa D, Dlouhy I, Salaverria I, Martin-Subero JI, Lopez-Guillermo A, Valera A, Campo E; Grup per l’Estudi dels Limfomes de Catalunya i Balears (GELCAB).

Am J Surg Pathol. 2017 Jul;41(7):877-886. doi: 10.1097/PAS.0000000000000839.

PMID:
28288039
3.

Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.

Culpin RE, Sieniawski M, Angus B, Menon GK, Proctor SJ, Milne P, McCabe K, Mainou-Fowler T.

Histopathology. 2013 Dec;63(6):788-801. doi: 10.1111/his.12223. Epub 2013 Oct 1.

PMID:
24117687
4.

High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas.

Shams TM.

J Egypt Natl Canc Inst. 2011 Dec;23(4):147-53. doi: 10.1016/j.jnci.2011.10.006. Epub 2011 Dec 9.

5.

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.

Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL, Kohrt HE, Houot R, Goldstein MJ, Zhao S, Natkunam Y, Advani RH, Gascoyne RD, Briones J, Tibshirani RJ, Myklebust JH, Plevritis SK, Lossos IS, Levy R.

Blood. 2011 Aug 4;118(5):1350-8. doi: 10.1182/blood-2011-03-345272. Epub 2011 Jun 13.

6.

Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma.

Cubedo E, Gentles AJ, Huang C, Natkunam Y, Bhatt S, Lu X, Jiang X, Romero-Camarero I, Freud A, Zhao S, Bacchi CE, Martínez-Climent JA, Sánchez-García I, Melnick A, Lossos IS.

Blood. 2012 Jun 7;119(23):5478-91. doi: 10.1182/blood-2012-01-403154. Epub 2012 Apr 19.

7.

LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.

Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS.

J Clin Oncol. 2008 Jan 20;26(3):447-54. Epub 2007 Dec 17.

PMID:
18086797
8.

Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.

Agostinelli C, Paterson JC, Gupta R, Righi S, Sandri F, Piccaluga PP, Bacci F, Sabattini E, Pileri SA, Marafioti T.

Histopathology. 2012 Jul;61(1):33-46. doi: 10.1111/j.1365-2559.2012.04198.x. Epub 2012 Mar 6.

PMID:
22394247
9.

LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.

Lossos C, Bayraktar S, Weinzierl E, Younes SF, Hosein PJ, Tibshirani RJ, Sutton Posthumus J, DeAngelis LM, Raizer J, Schiff D, Abrey L, Natkunam Y, Lossos IS.

Br J Haematol. 2014 Jun;165(5):640-8. doi: 10.1111/bjh.12801. Epub 2014 Feb 26. Review.

10.

A few good genes: simple, biologically motivated signatures for cancer prognosis.

Gentles AJ, Alizadeh AA.

Cell Cycle. 2011 Nov 1;10(21):3615-6. doi: 10.4161/cc.10.21.17835. Epub 2011 Nov 1. No abstract available.

11.

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.

Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, Gisselbrecht C, Brière J, Reyes F, Gaulard P, Feugier P, Labouyrie E, Tilly H, Bastard C, Coiffier B, Salles G, Leroy K; Groupe d'Etude des Lymphomes de l'Adulte.

Leukemia. 2008 Oct;22(10):1917-24. doi: 10.1038/leu.2008.188. Epub 2008 Jul 10.

12.

Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.

Charbonneau B, Maurer MJ, Fredericksen ZS, Zent CS, Link BK, Novak AJ, Ansell SM, Weiner GJ, Wang AH, Witzig TE, Dogan A, Slager SL, Habermann TM, Cerhan JR.

Am J Hematol. 2012 Sep;87(9):880-5. doi: 10.1002/ajh.23273. Epub 2012 Jun 20.

13.

Usefulness of HGAL and LMO2 immunohistochemistry in the identification of follicular lymphomas of the non-gastric gastrointestinal tract.

Chapman-Fredricks J, Younes SF, Fan YS, Sandoval-Sus JD, Natkunam Y, Lossos IS.

Appl Immunohistochem Mol Morphol. 2013 May;21(3):200-4. doi: 10.1097/PAI.0b013e31826399aa.

PMID:
22914613
14.

The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas.

Natkunam Y, Zhao S, Mason DY, Chen J, Taidi B, Jones M, Hammer AS, Hamilton Dutoit S, Lossos IS, Levy R.

Blood. 2007 Feb 15;109(4):1636-42. Epub 2006 Oct 12.

15.

BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.

Ding J, Dirks WG, Ehrentraut S, Geffers R, MacLeod RA, Nagel S, Pommerenke C, Romani J, Scherr M, Vaas LA, Zaborski M, Drexler HG, Quentmeier H.

Haematologica. 2015 Jun;100(6):801-9. doi: 10.3324/haematol.2014.120048. Epub 2015 Mar 13.

16.

[Expression and significance of HGAL and LMO2 in follicular lymphoma].

Zhang F, Luo D, Luo X, Chen Y, Xu J, Chen J, Zhuang H, Liu Y.

Zhonghua Bing Li Xue Za Zhi. 2016 Feb;45(2):83-5. doi: 10.3760/cma.j.issn.0529-5807.2016.02.003. Chinese.

PMID:
26879427
17.

Diagnostic Utility of the Germinal Center-associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms.

Menter T, Gasser A, Juskevicius D, Dirnhofer S, Tzankov A.

Appl Immunohistochem Mol Morphol. 2015 Aug;23(7):491-8. doi: 10.1097/PAI.0000000000000107.

PMID:
25203428
18.

Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma.

Chao C, Silverberg MJ, Martínez-Maza O, Chi M, Abrams DI, Haque R, Zha HD, McGuire M, Xu L, Said J.

Clin Cancer Res. 2012 Sep 1;18(17):4702-12. Epub 2012 Jun 18.

19.

LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype.

Patel JL, Pournazari P, Haggstrom SJ, Kosari F, Shabani-Rad MT, Natkunam Y, Mansoor A.

Histopathology. 2014 Jan;64(2):226-33. doi: 10.1111/his.12242. Epub 2013 Nov 6.

PMID:
24330148
20.

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.

Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G; German High-Grade Non-Hodgkin Lymphoma Study Group.

Blood. 2013 Mar 21;121(12):2253-63. doi: 10.1182/blood-2012-06-435842. Epub 2013 Jan 18.

Supplemental Content

Support Center